Harmony Biosciences Holdings, Inc. (HRMY)
NASDAQ:HRMY
Want to see HRMY full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.88Last Year’s EPS
0.68Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call portrayed a company with strong commercial momentum (17% revenue growth, reaffirmed $1.0–1.04B guidance), a well-funded balance sheet ($870.5M cash), advancing pipeline programs with near-term milestones (BP-205, pitolisant GR/HD, EPX-100), and an assertive IP defense strategy. Offsetting these positives were higher COGS and a sizable increase in operating expenses driven largely by a $32M upfront license fee, a decline in GAAP net income, muted cash flow for the quarter, ongoing litigation with timing/appeal uncertainty, and Q1 market access headwinds. On balance, highlights—particularly revenue traction, cash runway, and pipeline progress—outweigh the lowlights but the company faces near-term cost, legal and access execution risks.Company Guidance
Strong Revenue Growth
Q1 net product revenue of $215.4M, up 17% from $184.7M in Q1 2025; management reiterated full-year net revenue guidance of $1.00B to $1.04B.
Solid Patient Traction and Market Opportunity
Average ~8,500 patients on WAKIX in Q1 and ~8,600 at quarter end; diagnosed narcolepsy market ~80,000 patients (current penetration ~10–11%), indicating significant runway for continued patient growth.
Robust and Advancing Pipeline with Near-Term Milestones
Five ongoing Phase 3 registrational trials across distinct CNS indications. BP-205 (Orexin-2 agonist) on track for Phase 1 SAD PK topline data mid-2026 and U.S. IND mid-2026. Pitolisant GR on track for NDA submission in Q2 2026 (target PDUFA Q1 2027). Pitolisant HD is enrolling in two Phase 3 trials with topline data expected in 2027 (PDUFA 2028). EPX-100 OLE data showed median 50% seizure reduction in Dravet patients; registrational top-line data expected H1 2027 (PDUFA 2028).
IP Protection Progress and Litigation Outcomes Favorable to Date
Settled with 6 of 7 ANDA filers maintaining loss of exclusivity (LOE) until March 2030 (inclusive of 6 months pediatric exclusivity). Acquired Novitium license for an amorphous form with issued patents to 2042 and filed a new infringement suit against AET/Sandoz asserting that patent—management expresses confidence in a multilayered IP estate protecting pitolisant into the 2030s and potentially into the 2040s.
Commercial Investment and Execution
Completed field team expansion (~20% increase across field sales, remote sales and field reimbursement) with hires in place as of April 1. New online provider portal and enhanced reimbursement support to launch in Q2 to accelerate patient starts and dispense success.
Strong Balance Sheet and Focused BD Capacity
Cash and cash equivalents of $870.5M and modest debt of $160M at quarter end; leadership reiterates intent and capacity to deploy capital for business development targeting near-term revenue (2028–2032) and assets in Phase 3/market.
HRMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HRMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $32.78 | $31.42 | -4.15% |
Feb 24, 2026 | $26.87 | $28.19 | +4.91% |
Nov 04, 2025 | $29.33 | $30.72 | +4.74% |
Jul 31, 2025 | $35.48 | $35.18 | -0.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harmony Biosciences Holdings, Inc. (HRMY) report earnings?
Harmony Biosciences Holdings, Inc. (HRMY) is schdueled to report earning on Aug 11, 2026, Before Open (Confirmed).
What is Harmony Biosciences Holdings, Inc. (HRMY) earnings time?
Harmony Biosciences Holdings, Inc. (HRMY) earnings time is at Aug 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRMY EPS forecast?
HRMY EPS forecast for the fiscal quarter 2026 (Q2) is 0.88.